The current PE ratio of ANIP can't be determined, as the TTM EPS of -$0.55 is negative. The most recent PE ratio recorded for Ani Pharmaceuticals was 53.97 in June 2024.
Over the last ten years, the average PE ratio of Ani Pharmaceuticals has been 433.97. Over the past ten years, ANIP's PE ratio was at its highest in the Jun 2018 quarter at 6,680, with a price of $66.8 and an EPS of $0.01. The Sep 2015 quarter recorded the bottom point at 13.21, with a price of $39.51 and an EPS of $2.99.
Maximum annual increase: 429.36% in 2016
Year | PE ratio | Change |
---|---|---|
2023 | 64.12 | N/A |
2022 | N/A | N/A |
2021 | N/A | N/A |
2020 | N/A | N/A |
2019 | 120.92 | 251.82% |
2018 | 34.37 | N/A |
2017 | N/A | N/A |
2016 | 178.29 | 429.36% |
2015 | 33.68 | 55.85% |
2014 | 21.61 | N/A |
Stock name | PE ratio | Market cap |
---|---|---|
RPRX Royalty Pharma plc | 10.27 | $15.55B |
NVS Novartis AG | 12.03 | $207.63B |
JAZZ Jazz Pharmaceuticals plc | 16.79 | $7.56B |
CAH Cardinal Health Inc | 23.83 | $29.87B |
PFE Pfizer Inc | 33.07 | $142.41B |
TEVA Teva Pharmaceutical Industries Ltd | N/A | $19.35B |
CLDX Celldex Therapeutics Inc | N/A | $1.74B |
ANIP Ani Pharmaceuticals Inc | N/A | $1.17B |
The current price to earnings ratio of ANIP can't be calculated, as its EPS of -$0.55 is negative.
The 5-year average PE ratio for ANIP stock is 78.25.
Over the last ten years, the quarterly PE ratio reached a historic high of 6,680 in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.